CoChat
Sign Up
Cited by 157

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

Schaub, Franz X., Looser, Renate, Li, Sai, Hao-Shen, Hui, Lehmann, Thomas, Tichelli, Andre, Skoda, Radek C.·2010·Blood
DOI 10.1182/blood-2009-09-245381
Open this paper in CoChat — free account

Abstract

Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F. To examine the order of events, we performed colony assays and genotyped TET2 and JAK2 in individual colonies. In 4 of 8 myeloproliferative neoplasm patients, we found that some colonies with mutated TET2 carried wild-type JAK2, whereas others were JAK2-V617F positive, indicating that TET2 occurred before JAK2-V617F. One of these patients carried a germline TET2 mutation. However, in 2 other patients, we obtained data compatible with the opposite order of events, with JAK2 exon 12 mutation preceding TET2 mutation in one case. Finally, in 2 of 8 patients, the TET2 and JAK2-V617F mutations defined 2 separate clones. The lack of a strict temporal order of occurrence makes it unlikely that mutations in TET2 represent a predisposing event for acquiring mutations in JAK2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-09-245381

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 24

  1. Ono, 2002, LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23)., Cancer Res, 62, 4075
  2. Couronne, 2010, Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias., Leukemia, 24, 201, 10.1038/leu.2009.169 · DOI
  3. Kosmider, 2009, TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)., Blood, 114, 3285, 10.1182/blood-2009-04-215814 · DOI
  4. Mullighan, 2009, TET2 mutations in myelodysplasia and myeloid malignancies., Nat Genet, 41, 766, 10.1038/ng0709-766 · DOI
  5. Mohamedali, 2009, Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome., J Clin Oncol, 27, 4002, 10.1200/JCO.2009.22.6985 · DOI
  6. Abdel-Wahab, 2009, Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies., Blood, 114, 144, 10.1182/blood-2009-03-210039 · DOI · Paper page
  7. Jankowska, 2009, Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms., Blood, 113, 6403, 10.1182/blood-2009-02-205690 · DOI · Paper page
  8. Tefferi, 2009, Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML., Leukemia, 23, 1343, 10.1038/leu.2009.59 · DOI
  9. Tefferi, 2009, Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates., Leukemia, 23, 900, 10.1038/leu.2009.37 · DOI
  10. Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms., Blood, 100, 2292, 10.1182/blood-2002-04-1199 · DOI
  11. Tefferi, 2007, Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel., Blood, 110, 1092, 10.1182/blood-2007-04-083501 · DOI
  12. Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes., Blood, 114, 937, 10.1182/blood-2009-03-209262 · DOI
  13. Kralovics, 2003, Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders., Blood, 102, 1869, 10.1182/blood-2003-03-0744 · DOI
  14. Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders., N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 · DOI · Paper page
  15. Schaub, 2009, Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F., Blood, 113, 2022, 10.1182/blood-2008-07-167056 · DOI
  16. Gregg, 2000, A polymorphism of the X-linked gene IDS increases the number of females informative for transcriptional clonality assays., Am J Hematol, 63, 184, 10.1002/(SICI)1096-8652(200004)63:4<184::AID-AJH4>3.0.CO;2-I · DOI
  17. Liu, 2003, Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin., Blood, 101, 3294, 10.1182/blood-2002-07-2287 · DOI
  18. Kralovics, 2006, Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders., Blood, 108, 1377, 10.1182/blood-2005-11-009605 · DOI
  19. Scott, 2007, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis., N Engl J Med, 356, 459, 10.1056/NEJMoa065202 · DOI
  20. Li, 2008, Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations., Blood, 111, 3863, 10.1182/blood-2007-09-111971 · DOI
  21. Beer, 2009, Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones., Br J Haematol, 144, 904, 10.1111/j.1365-2141.2008.07560.x · DOI
  22. Olcaydu, 2009, A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms., Nat Genet, 41, 450, 10.1038/ng.341 · DOI
  23. Jones, 2009, JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms., Nat Genet, 41, 446, 10.1038/ng.334 · DOI
  24. Saint-Martin, 2009, Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms., Blood, 114, 1628, 10.1182/blood-2009-01-197525 · DOI

Cited by

See all 157

Metadata

Authors
Schaub, F. X., Looser, R., Li, S., Hao-Shen, H., Lehmann, T., Tichelli, A., & Skoda, R. C.
Affiliations
  • Department of Biomedicine, Experimental Hematology,
  • Department of Hematology, and
  • Division of Diagnostic Hematology, University Hospital Basel, Basel, Switzerland
Venue
Blood
Publisher
American Society of Hematology
Published
2010-03-11
Volume
115
Issue
10
Pages
2003-2007
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2009-09-245381
Cited by
157
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1182/blood-2009-09-245381
The paper
Schaub, F. X., Looser, R., Li, S., Hao-Shen, H., Lehmann, T., Tichelli, A., & Skoda, R. C. (2010). Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood-2009-09-245381